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Do circulating cytokines really matter in sepsis? Sepsis remains clinically significant biological effects at cell or organ
the major cause of mortality worldwide, claiming millions of level.
lives each year. The past decade has seen major advances in
the understanding of the biological mechanisms involved in
this complex process. Unfortunately, no definitive therapy yet WHAT IS THE RELEVANCE OF CIRCULATING
exists that can successfully treat sepsis and its complications. CYTOKINES IN SEPSIS ?In this review, we will address the significance of circulating
The sensitivity of monoclonal antibodies and assayscytokines in the pathophysiology of sepsis and its relevance to
new approaches in extracorporeal therapies. to detect cytokines in plasma, the bound versus free
cytokine ratio, and cytokine renal clearance are the most
important factors influencing cytokine plasma levels. In
fact, the presence or absence of detectable levels of cyto-Sepsis is a systemic immune response that leads to
kines within biological fluids reflects a complex balancemultiple organ failure [1]. Initially described as mainly
between enhancing and inhibitory signals acting on pro-due to the overproduction of pro-inflammatory factors,
ducer cells, production and catabolism, cytokine bindingits pathogenesis is now viewed as much more complex.
to target cells, and the modulation of their receptors onInitially, the concept of blood purification by extracorpo-
the cell surface [5]. Furthermore, their presence does notreal therapies stemmed from the assumption that non-
necessarily parallel their activity, and a possible interplayspecific removal of several inflammatory mediators would
between a given cytokine and its relative inhibitor (ifimprove outcome in septic shock [2]. However, useful
known) should be considered [5]. Despite the fact thatconvective removal of mediators from the human septic
high plasma levels may reflect increased production,circulation has not been achieved to date, although many
these levels do not necessarily represent enhanced bio-cytokines have a molecular weight below the theoretical
activity. There are several factors that may help to ex-cut-off point of commercial membranes currently in use
plain the incongruities seen in the cytokine-bioactivity[3]. The recent finding that the ultrafiltration dose is
story. One such factor is genotypic predisposition. Endo-correlated to outcome in critically ill patients with acute
toxin-induced cytokine production differs among indi-renal failure strongly suggests the concept of a “sepsis
viduals. This genetically determined trait is referred todose” (removal of sepsis-associated mediators) in con-
as endotoxin responsiveness [5]. However, subjects whotrast to a “renal dose” in critically ill patients without
are both highly endotoxin-responsive (i.e., geneticallysystemic inflammation [4].
inclined to produce larger amounts of pro-inflammatoryBased on the provocative title of this review, we will
cytokines such as tumor necrosis factor-), or less endo-briefly address the complexity of the host response in
toxin-responsive (i.e., lack of TNF-production but in-sepsis, particularly in respect to extracorporeal therapies,
creased anti-inflammatory production, such as interleu-with the prejudice that looking at circulating cytokines
kin-10 [IL-10]) are predisposed to poorer prognoses [6].has only little value from a pathophysiologic viewpoint.
In intensive care medicine, blocking one mediator hasFurthermore, we will discuss the concept that testing
not led to measurable outcome improvements in patientsinnovative extracorporeal techniques on the basis of
with sepsis [7]. Furthermore, the time point in the septictheir effect on circulating cytokines may overlook more
process of therapeutic intervention seems to be crucial.
As the network acts like a cascade, early intervention
would seem most beneficial. On the other hand, sepsisKey words: sepsis, septic shock, cytokines, endotoxin, LPS, hemofiltra-
tion, plasmapheresis, adsorption, multiorgan failure, plasma filtration. does not fit a one-hit-model. Neither single-mediator-
directed nor one-time interventions, therefore, seem ap- 2003 by the International Society of Nephrology
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propriate. One of the major criticisms attributed to con- times greater than the best reported ex vivo sieving coef-
ficients for commercially available membranes with nom-tinuous blood purification therapy in sepsis—its lack of
specificity—could turn out to be a major strength. Unspe- inal cut-off points of approximately 30 kD [16]. The
results from these authors were less than those achievedcific removal of soluble mediators, be they pro- or anti-
inflammatory, without completely eliminating their ef- by using a plasma filtration membrane (0.70 for IL-8,
1.22 for TNF, 1.48 for IL1, and 0.55 for IL-6) [15].fect may be the most logical approach to a complex and
long-running process like sepsis. The concept of cutting However, it is interesting to note that the ultimate mem-
brane clearances of cytokines were greater in the studypeaks of soluble mediators (e.g., through continuous he-
mofiltration) is a paradigm we call “the peak concentra- with a reduced nominal cut-off [14], since with the latter
membrane, a greater filtrate flow could be achieved bytion hypothesis” [8].
a higher transmembrane pressure than those recorded
with a plasma filtration membrane [15].
BLOOD PURIFICATION BY
However, we, as the authors of the two above-men-
EXTRACORPOREAL THERAPY: DOES
tioned publications, feel the need to strongly advise the
REMOVAL OF CIRCULATING CYTOKINES
reader about the limitations of ex vivo studies of this
REALLY MATTER?
kind. Although in both a significant reduction of different
For several years, the issue of the capability of hemo- cytokines was claimed, total body clearance in the in
filtration to remove inflammatory mediators has re- vivo situation is a completely different story.
mained controversial. Numerous ex vivo, as well as ani- Using an experimental model of acute endotoxemia
mal and human studies, have shown that synthetic filters in the rabbit, we showed that nonselective adsorption of
in common use in hemofiltration can extract nearly every cytokines and other pro-inflammatory mediators could
substance involved in sepsis to a certain degree [9]. On improve survival in the absence of any significant change
the other hand, significant clinical benefits in terms of in TNF-dependent plasma activity [17]. Much more
hemodynamic improvement have been achieved even effective than the effect on circulating cytokines is the
without measurable decreases in cytokine plasma levels impact on the functional responses of cells implicated in
[10]. the pathogenesis of sepsis. In a very recent study [18],
Obviously, the removal of substances other than those we showed that nonselective removal of mediators could
measured cytokines was responsible for the achieved ef- restore leukocyte responsiveness in patients with septic
fect. Alternatively, bioactive substances including some shock. Immunomodulating substances (with molecular
of the measured cytokines were removed, causing the weight in the range of 5 to 50 kD) may be eliminated
observed beneficial effect. by diffusion, adsorption, or convection, depending on the
In this context, a step in further clarifying the impact rather variable cut-off of highly permeable membranes
of extracorporeal therapy on cell function has been taken (range from 30 to 40 kD) [9]. In a randomized, prospec-
by measuring a more downstream event integrating sev- tive study on the effect of coupled plasma filtration-
eral cytokine influences: monocyte responsiveness [11, 12]. adsorption (CPFA) in human septic shock, Ronco et al
In spite of some encouraging results, the achievable [18] showed that the increase in mean arterial pressure
clinical benefit with continuous renal replacement therapies was remarkably higher with CPFA than with conven-
(using conventional filters and flow rates) in sepsis has been tional mixed convective-diffusive continuous therapy
disappointing [13]. Consequently, we sought to improve the (CVVHDF). In these patients, the increase of mean arte-
efficiency of soluble mediator removal by increasing the rial pressure was achieved using norepinephrine at much
amount of plasma water exchange (i.e., increasing ultrafil- a lower dose in the CPFA than in conventionally treated
tration rates) [8]. However, apart from increasing ultrafil- patients. Of interest, these hemodynamic changes oc-
tration rates, higher removal rates of middle molecular curred in parallel with significant immunomodulatory
weight molecules could be achieved by enlarging the changes. Although no changes in TNF and IL-10 plasma
pore size of membranes. Ex vivo models have proved levels could be observed (despite complete adsorption
useful in precisely calculating sieving coefficients and of these cytokines by the adsorbent), TNF production
clearance values using large pore synthetic membranes. induced ex vivo by endotoxin increased more in CPFA
Two publications illustrate the advantages provided by (5-fold) than in CVVHDF. IL-10 appeared to be an
examining membrane handling as well the limitations of important but not an exclusive mediator of reduced leu-
this approach [14, 15]. In their paper, Cole et al [14], kocyte responsiveness.
using a large pore membrane (nominal cut-off: 100 kD),
found an average sieving coefficient of 0.30 for interleu-
CONCLUSIONSkin-(IL-) 8, 0.56 for TNF, 0.61 for IL-1, and 1.34 for
IL-6; the respective membrane clearances were 24.2, An array of mostly acutely produced mediators plays
a strategic role in the septic syndrome. Defining the44.9, 48.5, and 106.8 mL/min. These results are 2 to 10
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